Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Airboss of America Corp
Alimera Sciences, Inc. - Common Stock
Amplify Junior Silver Miners ETF
Aramark Common Stock
Aurora Spine Corp
BWX Technologies, Inc. Common Stock
Biotricity, Inc. - Common Stock
Brunswick Corporation Common Stock
Citius Oncology, Inc. - Common Stock
Cocrystal Pharma, Inc. - Common Stock
DatChat, Inc. - Common Stock
Dmg Blockchain
Dorchester Minerals, L.P. - Common Units Representing Limited
Emergent Metals Corp
Euro Sun Mining Inc
Exela Technologies, Inc. - 6.00% Series B Cumulative Convertible Perpetual
Fast Retailing CO Ltd
Fidelity Disruptive Finance ETF
Fpx Nickel Corp
GD Culture Group Limited - Common Stock
Impact BioMedical, Inc. Common Stock
Integral Ad Science Holding Corp. - Common Stock
Intercontl Hotls Ord New
Janus Henderson Small Cap Growth Alpha ETF
Maison Solutions Inc. - Class A Common Stock
Meteoric Resources Ltd
Mitsui Kinzoku ADR
Morgan Stanley India Investment Fund, Inc. Common Stock
Nintendo CO Ltd Ord
Novaccess Global Inc
Palvella Therapeutics, Inc. - Common Stock
Peer To Peer Network
Portage Biotech Inc. - Common Stock
Prairie Operating Co. - Common Stock
Protagenic Therapeutics, Inc. - Common Stock
Pt Xlsmart Telcom ADR
Puma Ag Rudolf Dassler Sport
Reconnaissance Energy Africa Ltd
SSR Mining Inc. - Common Stock
Salem Media Group, Inc. - Class A Common Stock
Saratoga Investment Corp New
Simpson Manufacturing Company, Inc. Common Stock
Super Micro Computer, Inc. - Depositary Shares
TOP Ships Inc. - Common Stock
Traction Uranium Corp
Uniper Se
Verano Hldgs Corp
Verses Ai Inc
Vestas Wind Sys ADR
Volato Group, Inc. Class A Common Stock
Voyager Acquisition Corp - Class A Ordinary Shares
Wipro Limited Common Stock
Woodward, Inc. - Common Stock
Worldline Sa Ord
XIAO-I Corporation - American Depositary Shares
ZW Data Action Technologies Inc. - Common Stock
iShares Core S&P Small-Cap ETF
micromobility.com Inc. - Class A Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Warrant
(NQ:
LEXXW
)
0.0012
UNCHANGED
Last Price
Updated: 3:34 PM EST, Jan 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Warrant
< Previous
1
2
3
4
5
6
7
8
9
Next >
Lexaria Announces Results from Animal Study GLP-1-A26-1
October 15, 2026
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
October 06, 2026
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Updates Financial Position
September 17, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 09, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
September 08, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 04, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Receives USD$2.6 Million Tax Rebate Payment
September 01, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
August 24, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Enters a Material Transfer Agreement With PegBio
August 13, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Announces Effective Date for Reverse Stock Split
July 30, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria Updates Business Development
July 06, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
June 25, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
June 23, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
June 17, 2026
From
Lexaria Bioscience Corp.
Via
ACCESS Newswire
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 09, 2026
Via
ACCESS Newswire
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
June 03, 2026
Via
ACCESS Newswire
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
May 19, 2026
Via
ACCESS Newswire
Lexaria Bioscience Releases Second Episode of Investor Video Series
May 07, 2026
Via
ACCESS Newswire
Lexaria Updates Progress on Human Study #7
May 05, 2026
Via
ACCESS Newswire
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
May 01, 2026
Via
ACCESS Newswire
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
April 29, 2026
Via
ACCESS Newswire
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
April 23, 2026
Via
ACCESS Newswire
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
April 21, 2026
Via
ACCESS Newswire
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
April 15, 2026
Via
ACCESS Newswire
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
April 07, 2026
Via
ACCESS Newswire
Lexaria to Begin New Human Clinical Study in GLP-1
April 01, 2026
Via
ACCESS Newswire
Lexaria's Robust Patent Portfolio Continues to Grow
March 26, 2026
Via
ACCESS Newswire
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
March 24, 2026
Via
ACCESS Newswire
Lexaria Announces New R&D Plans for 2026
March 04, 2026
Via
ACCESS Newswire
Lexaria Announces Positive Final Results From Human Pilot Study #5
February 05, 2026
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
